Introduction
Malaria remains one of the major causes of morbidity and mortality in both endemic and non-endemic areas in Zimbabwe. Malaria occurs in epidemic forms in Zimbabwe. There are, however, a few areas where malaria is endemic. The most common malaria complications in Zimbabwe are anaemia, hypoglycaemia, cerebral malaria and renal failure. Possible factors that influence the natural course of a malaria illness are lack of immunity to malaria, inadequate case m anagem ent and probably the hum an immunodeficiency virus (HIV) infection. Most studies on the relationship between HIV and malaria have shown no association.1 '3 Zimbabwe has an organised malaria control programme which came out of the World Health Organization (WHO) Global Malaria Control Strategy of 1993.4The main control methods in Zimbabwe are: indoor residual spraying, adequate case management and surveillance. Zimbabwe is one of the few countries in Southern Africa still using chloroquine as the first line drug of choice in the treatment of uncomplicated Plasmodium falciparum malaria. Other countries now use sulphadoxine-pyrem etham ine (Fansidar).
In 1997, Zimbabwe reported more than a million malaria cases, 68 751 malaria admissions and 2 808 malaria deaths: giving a case fatality rate (CFR) of 4.1%. Mashonaland West Province had an outbreak of malaria in 1997, and the most affected districts were Hurungwe and Makonde. The m alaria control program m e is well organised in Mashonaland West Province. The province reported a high case fatality rate of 7.9% in 1997 (higher than the national CFR), probably due to the outbreak.
The health policy in Zimbabwe is based on the concept of Primary Health Care strategy, that advocates equity in health, acceptable and accessible health services as some of its components. The past 19 years has seen the improvement in accessibility and availability of health services to the general population. The question that can be asked is why is there a continued malaria problem in a country where control methods are good, health services are easily accessible and drugs for malaria treatment are available. Could it be due to the current HIV pandemic? Some authors in Zimbabwe failed to establish whether there was any association between HIV and malaria.s-6 This study was carried out to determine whether HIV infection influenced the natural progression of malaria illness at a rural hospital in Zimbabwe.
Materials and Methods
A cohort study was conducted at a rural hospital in Hurungwe district from 18 February to 30 May 1999. Malaria positive patients who were HIV positive were the exposed cases and the HIV negative cases were the nonexposed. The outcome of interest was the development of severe and complicated malaria. The outcome of interest was defined as a slide positive malaria patient who developed signs of impaired consciousness, fits and convulsions, haemoglobin of less than 8g/dl, parasite density of 2% or more, jaundice, passing dark urine, breathlessness, low diastolic blood pressure, persistent vomiting, bleeding from mucosa and renal failure.7 All the patients recruited into the study were admitted for observation of severe and complicated malaria. The Pocock's statistical formula was used to calculate the sample size.8 Assuming that 2.5% of the HIV negative malaria patients and 15% HIV positive malaria patients would develop severe and complicated malaria,® and considering power of 80% and an alpha of 5 %, the minimum sample size required was 77 HIV negative and 77 HIV positive patients.
After suspecting that a patient had malaria, about 10 mis of venous blood was collected for the following tests: 1. Malaria rapid test using the Biotech Rapid Malaria Test. The test is an antigen capture assay which detects the presence of soluble protein, histidine-rich protein II (PHRP-II), found in, and released from the infected red blood cells. The sensitivity of the test ranges from 92% to 100%. 2. Blood slide microscopy for confirmation of the rapid test. 3. Full blood count and differential count. 4. CD4 count using the TriTest CD3FITC/CD88PE/ CD45 per CP reagent, supplied by Becton Dickinson Inco. The reagent is a three colour direct immunofluoresence reagent for identifying and detecting the percentages and absolute counts of mature human T-lymphocytes. The CD4 count test was done as a proxy to objectively assess the degree of HIV infection in the malaria patients. 5. Rapid HIV-1 test using the Immuno Chemical Laboratory (ICL) dipstick test kit from Thailand. The test uses synthetic peptide antigens to capture antibodies to the HIV-1 and 2. The ICL Dipstick has a sensitivity of 100% and a specificity of above 98.4% and is comparable to any conventional ELISA currently in use.
Data Collection Tools.
A structured questionnaire and a checklist were used to collect data. The questionnaire was administered to patients when a diagnosis of positive malaria was made in order to collect information on possible confounding factors and demographic data. In unconscious patients the questionnaire was administered to relatives. The checklist was used to enter blood results, other investigations done and duration of hospital stay.
Data Analysis.
Data was analysed using the Epi Info package. The statistical methods used were the Yates' corrected Chisquare test or the Fisher's exact test when expected frequencies were less than five. In the preliminary analysis (bivariate analysis) it was sufficient to report only p values in order to identify confounding factors. The relative risk (95 % confidence interval) was reported as a measure of the magnitude of the association. The cut off point for age was determined by using a method called the 'receiver operator characteristic (ROC) curve', which maximises sensitivity and specificity.10 In this study the age cut off point was 22 years. A result with a p value of less than 5 % was considered statistically significant.
Results

Background Characteristics.
A total of 2 237 clinical malaria cases were reported at Hurungwe Rural Hospital, from 1 January to 30 May 1999. A total of 1 862 clinical cases were reported during the study period and 659 (35.4%) clinical malaria cases were investigated. Out of the 659 clinical malaria cases, 237 (36.0%) were confirmed malaria cases. Eighty two (34.6% of confirmed malaria cases or 12.4% of clinical cases recorded) were HIV positive. The total number of severe and complicated malaria cases was 129(54.4% of confirmed malaria cases).
The commonly reported complications were parasite count of 2% or more (38.5%), anaemia (29.0%), cerebral malaria (23.1%), low blood pressure (8.3%) and renal failure (1.2%). There were a total of 14 deaths giving a case fatality rate of 5.9% in confirmed cases. Amongst the 14 malaria deaths recorded, 11 were HIV positive and three were HIV negative. The HIV positive malaria cases, which developed severe and complicated malaria were 72,30.4% of confirmed malaria cases. The HIV positive malaria patients were more than two times (RR=2.47,95% C.I.=1.77 to 3.45 and p<0.001) more likely to die from malaria than HIV negative malaria patients. The risk of developing severe and complicated malaria was 2.39 (95% C.I.=1.91 to 2.98 and p<0.001) times more in HIV positive malaria patients than in HIV negative malaria patients.
There were 101 slide positive malaria patients who were tested for CD4 lymphocyte count levels. Patients who had CD4 lymphocyte counts of less than 500 were 75 (74.3%) and 38 (37.6%) had CD4 lymphocyte counts of less than 
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200. The CD4 lymphocyte count was used to determine the
Identification of confounding factors in the relationship
stage of the HIV infection in the HIV positive malaria between HIV infection and the development o f severe patients. However, patients with low CD4 counts of less and complicated malaria (Tables I and II) .
than 500 were not associated with an increased risk of The assessment of factors that could have had possible developing severe and complicated malaria (RR=1.11, confounding effects on the relationship between HTV 95% C.I.=0.86 to 1.44 and p=0.540).
infection and the development of severe and complicated malaria revealed that the mode of transport to the nearest health centre was the only confounding factor. After adjusting for this confounding factor, the relationship between HIV and the development of severe and complicated malaria remained significant (RR=2.35,95% C.I. =1.85 to 2.98 and p<0.001).
Discussion
The malaria positivity rate of 36.0% found in this study was consistent with the 25 to 40% positivity rate in Mashonaland West, depending on the area. There was a rather high HIV sero-prevalence rate of 34.6% in the malaria confirmed cases when compared to the national sero-prevalence rate of around 22%. This high prevalence of malaria in HIV positive patients was also reported in Kinshasa, Zaire by Greenberg et al. 1 They also showed that HIV positive children were investigated for fever more often than HIV negative children. The increase in malaria incidence may, therefore, be due to the fact that more HIV positive patients tend to be investigated more for malaria when they develop a fever than HIV negative patients. Although these results were not comparable to the national results, these results can be used to justify the establishment of an HIV sentinel site at the hospital to be able to quantify the transmission patterns in Hurungwe. The malaria case fatality rate of 5.9% was comparable to the national figure of 4.1% in 1997. It was interesting to note that 11 out of the 14 deaths were HIV positive. In the current study the risk of developing severe and complicated malaria in the HIV positive group was 2.35 times higher than in the HIV negative group. Chandramohan and Greenberg2 also reported that the case fatality rate of severe and complicated malaria patients was more than twice in the HIV positive patients compared to HIV negative patients. However, studies done elsewhere in Rwanda,3 Zambia 11 and the Democratic Republic of Congo1 found no association between HIV infection and the development of severe and complicated malaria. In all these studies the setting was a central hospital where critically ill patients were referred and this may have affected the apparent relationship between HIV and the progression of malaria.
The low CD4 count in the HIV negative malaria patients was expected since acute malaria causes lymphopaenia. However, the degree of lymphopaenia and the effects of chronic malaria are not known. The lack of association between CD4 count and severe and complicated malaria could not be explained and appears to contradict the significant association found between HIV infection and m alaria. A new syndrom e called idiopathic CD4 lymphopaenia (ICL), may explain these findings or it may well be due to chance.12
Conclusion
Infection with HIV was significantly associated with the development of severe and complicated malaria in Hurungwe district. This study clearly demonstrated that HIV infection modifies the progression of a malaria illness. Most studies done on HIV and malaria had shown no significant association except that malaria case fatality was high in those patients who were HIV positive. Future studies should probably focus on identifying how HIV modifies the progression of malaria and whether HIV positive malaria patients need a different treatment approach from the current malaria treatment protocol.
The CD4 lymphocyte count was not associated with the outcome of interest. This could be a spurious finding. Further studies are required to determine the association of CD4 lymphocyte count and the development of severe and complicated malaria. Recommendations.
1.
Voluntary HIV counselling and testing must be advocated, made more available and cheap so that patients can be educated on the need to seek treatment early if they are HIV positive. 2.
Studies to determine the normal levels of CD4 lymphocyte counts in people living in malaria endemic areas must be carried out so that clinicians can interpret CD4 lymphocyte counts appropriately.
3.
Similar studies in Zimbabwe are necessary so that the prevalence of HIV in malaria patients can be documented and appropriate changes to prevention and treatment can be made.
